Revolutionizing diabetic retinopathy screening with AI
AEYE Health receives first-ever FDA approval for fully autonomous AI diabetic retinopathy diagnostic, combining mobility and affordability.
AEYE Health, specializing in artificial intelligence-based imaging and diagnostics, has announced receiving the first-ever FDA approval for a fully autonomous AI diagnosing diabetic retinopathy. The integration of fully autonomous AI with a handheld device presents a new, cost-effective screening solution for the leading cause of blindness in the working-age population. The mobile solution is particularly suitable for point-of-care testing, enabling examinations wherever patients are – whether in clinics or at home.
The AEYE-DS technology has already been FDA-cleared and commercially available with a tabletop imaging device, and will now become the first and only artificial intelligence solution allowing autonomous screening anywhere through the Optomed Aurora - a handheld device.
AEYE-DS is also the only solution capable of screening patients with just one image per eye, with an image quality exceeding 99%.
Jerusalem Post Store
`; document.getElementById("linkPremium").innerHTML = cont; var divWithLink = document.getElementById("premium-link"); if (divWithLink !== null && divWithLink !== 'undefined') { divWithLink.style.border = "solid 1px #cb0f3e"; divWithLink.style.textAlign = "center"; divWithLink.style.marginBottom = "15px"; divWithLink.style.marginTop = "15px"; divWithLink.style.width = "100%"; divWithLink.style.backgroundColor = "#122952"; divWithLink.style.color = "#ffffff"; divWithLink.style.lineHeight = "1.5"; } } (function (v, i) { });